Xinmai Medical's revenue and net profit will both grow in 2025. Chairman Sun Hongbin, born after 1975, previously worked at KPMG Huazhen.

NightAirdropper · 2026-02-28T01:12:31+00:00

Xinmai Medical releases the 2025 annual performance quick report, with total operating revenue of 1.351 billion yuan, an increase of 11.96% year-on-year; net profit of 563 million yuan, an increase of 12.17% year-on-year. Overseas sales revenue exceeds 250 million yuan, with a growth rate of over 55%. The company's products cover 49 countries and regions. Chairman Sun Hongbin has extensive experience in finance and management.

NightAirdropper

2026-02-28 01:12:31

Abstract generation in progress

Rui Cai Finance Liu Zhiying On February 27, Xinmai Medical (SH688016) released the 2025 Annual Performance Briefing Announcement.

During the reporting period, the company achieved a total operating revenue of 1.351 billion yuan, an increase of 11.96% year-on-year; net profit attributable to the parent company’s owners was 562.3 million yuan, up 12.17% year-on-year; net profit attributable to the parent company’s owners after deducting non-recurring gains and losses was 502.17 million yuan, an increase of 26.97%.

At the end of the reporting period, the company’s total assets were 4.64 billion yuan, an increase of 8.13% from the beginning of the year; owners’ equity attributable to the parent company was 4.076 billion yuan, up 7.48%; net asset per share attributable to the parent company was 33.63 yuan, an increase of 9.03%.

During the reporting period, the company’s overseas sales revenue exceeded 250 million yuan, a year-on-year increase of over 55%, accounting for more than 18% of the company’s total revenue. The company continued to promote cooperation with regional industry clients worldwide and actively worked on market access and promotion of aortic and peripheral intervention products in Europe, Latin America, Asia-Pacific, and other countries. As of the end of the reporting period, the company’s product sales covered 49 countries and regions (including China).

According to Rui Cai Society, Xinmai Medical Chairman Sun Hongbin has a background in finance, holding a bachelor’s degree in economics from Shanghai Jiao Tong University.

Sun Hongbin, born in October 1975, holds a bachelor’s degree in economics from Shanghai Jiao Tong University, is a member of the Chinese Institute of Certified Public Accountants, and a Chartered Financial Analyst. He previously served as Assistant Manager at KPMG Huazhen LLP, CFO and General Manager of Otsuka (China) Investment Co., Ltd., Chairman of Shanghai MicroPort Medical Robot (Group) Co., Ltd., and currently serves as CFO of MicroPort Investment Holdings Limited, CFO of MicroPort Medical Science Co., Ltd., OMC Chairman, CEC Rotating Chairman, GMC, and ICC member.

Related company: Xinmai Medical SH688016

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.